Hanson & Doremus Investment Management Has $710,000 Stake in Eli Lilly And Co (NYSE:LLY)

Hanson & Doremus Investment Management increased its holdings in shares of Eli Lilly And Co (NYSE:LLY) by 6.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,404 shares of the company’s stock after purchasing an additional 347 shares during the period. Hanson & Doremus Investment Management’s holdings in Eli Lilly And Co were worth $710,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the company. Selective Wealth Management Inc. bought a new position in Eli Lilly And Co in the third quarter valued at approximately $25,000. Enterprise Trust & Investment Co acquired a new stake in Eli Lilly And Co in the 3rd quarter valued at approximately $27,000. Garrett Wealth Advisory Group LLC acquired a new stake in Eli Lilly And Co in the 3rd quarter valued at approximately $29,000. Quest Capital Management Inc. ADV acquired a new stake in Eli Lilly And Co in the 3rd quarter valued at approximately $34,000. Finally, Accurate Investment Solutions Inc. acquired a new stake in Eli Lilly And Co in the 4th quarter valued at approximately $40,000. Institutional investors and hedge funds own 76.45% of the company’s stock.

In related news, CFO Joshua L. Smiley purchased 929 shares of the stock in a transaction on Friday, October 25th. The shares were purchased at an average cost of $107.59 per share, with a total value of $99,951.11. Following the acquisition, the chief financial officer now directly owns 31,524 shares in the company, valued at $3,391,667.16. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO David A. Ricks purchased 4,615 shares of the stock in a transaction on Friday, October 25th. The stock was bought at an average cost of $108.38 per share, for a total transaction of $500,173.70. Following the completion of the acquisition, the chief executive officer now owns 157,405 shares in the company, valued at $17,059,553.90. The disclosure for this purchase can be found here. Over the last three months, insiders bought 8,405 shares of company stock worth $909,004 and sold 1,780,504 shares worth $219,697,912. 0.11% of the stock is owned by corporate insiders.

A number of equities research analysts recently issued reports on the company. Argus lifted their target price on Eli Lilly And Co from $145.00 to $165.00 and gave the company a “buy” rating in a research report on Monday, December 30th. TheStreet raised Eli Lilly And Co from a “c+” rating to a “b-” rating in a research report on Friday, November 8th. Cantor Fitzgerald reissued a “buy” rating and issued a $143.00 target price on shares of Eli Lilly And Co in a research report on Monday, December 2nd. Morgan Stanley raised Eli Lilly And Co from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $116.00 to $150.00 in a research report on Wednesday, December 18th. They noted that the move was a valuation call. Finally, Bank of America started coverage on Eli Lilly And Co in a research report on Wednesday, October 16th. They set a “buy” rating and a $133.00 price target on the stock. Five equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $135.67.

NYSE LLY traded down $1.04 during trading on Thursday, reaching $140.95. 52,606 shares of the company’s stock were exchanged, compared to its average volume of 3,224,563. The company has a debt-to-equity ratio of 4.09, a current ratio of 1.17 and a quick ratio of 0.88. The business has a 50 day moving average price of $127.65 and a 200-day moving average price of $115.42. The stock has a market capitalization of $135.04 billion, a P/E ratio of 25.41, a PEG ratio of 1.84 and a beta of 0.20. Eli Lilly And Co has a fifty-two week low of $101.36 and a fifty-two week high of $141.69.

Eli Lilly And Co (NYSE:LLY) last posted its quarterly earnings results on Wednesday, October 23rd. The company reported $1.48 earnings per share for the quarter, beating analysts’ consensus estimates of $1.43 by $0.05. Eli Lilly And Co had a return on equity of 107.99% and a net margin of 35.10%. The business had revenue of $5.48 billion for the quarter, compared to analysts’ expectations of $5.50 billion. During the same quarter in the prior year, the business earned $1.39 EPS. The firm’s revenue for the quarter was up 3.2% on a year-over-year basis. On average, analysts forecast that Eli Lilly And Co will post 5.8 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 14th will be given a $0.74 dividend. The ex-dividend date of this dividend is Thursday, February 13th. This is a positive change from Eli Lilly And Co’s previous quarterly dividend of $0.65. This represents a $2.96 annualized dividend and a dividend yield of 2.10%. Eli Lilly And Co’s dividend payout ratio is presently 46.49%.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Further Reading: Dividend

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.